Adial Pharmaceuticals Inc.

12/14/2021 | Press release | Archived content

Correspondence (Form CORRESP)

1180 Seminole Trail, Suite 495
Charlottesville, VA 22901
(434) 422-9800

December 14, 2021

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance

100 F Street, N.E.
Washington, D.C. 20549

Re:

Adial Pharmaceuticals, Inc.

Registration Statement on Form S-3

File No: 333-261509

Request for Acceleration

Ladies and Gentlemen:

Adial Pharmaceuticals, Inc. (the "Registrant") hereby requests that the United States Securities and Exchange Commission (the "Commission") take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-261509), to become effective on Thursday, December 16, 2021, at 9:00 a.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. or Patrick J. Egan, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 or Mr. Egan at (914) 557-5574 or (212) 907-6457 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.

Very truly yours,
ADIAL PHARMACEUTICALS, INC.
By: /s/ William B. Stilley III
Name: William B. Stilley III
Title: Chief Executive Officer
cc:

Leslie Marlow, Esq., Gracin & Marlow, LLP

Patrick J. Egan, Esq., Gracin & Marlow, LLP